Predict Immunotherapy Treatment Benefit As Early As Week 61
A personalized tumor-informed circulating tumor DNA assay covered by Medicare for immune checkpoint inhibitor (ICI) treatment response monitoring across all solid tumor types and stages of cancer.
The INSPIRE trial validated Signatera™ ctDNA testing as an early biomarker of immunotherapy response with 98% baseline ctDNA detection across 94 patients and 25 solid tumor types.1
Early Changes in ctDNA Levels Predict Treatment Benefit
Changes in ctDNA levels from baseline to week 6 (start of cycle 3) are predictive of immunotherapy benefit across cancer types.1
ctDNA Clearance at Any Time Correlates with Overall Survival
Overall survival was 100% in patients who experienced ctDNA clearance for at least one on-treatment time point.1
Watch How Signatera™ Informs Treatment Strategy
Know More With a Single Tumor Sample
Bespoke IO Clinical Trial
The BESPOKE IO clinical study is currently enrolling patients living with colorectal cancer, non-small cell lung cancer, and melanoma who will receive standard of care treatment with ICIs. The study will determine how longitudinal Signatera™ testing impacts treatment decisions and early detection of disease progression when integrated as part of routine assessment of tumor response.
Natera and its collaborators will collect clinical utility and outcomes data for two years from patient enrollment. This data will help demonstrate how Signatera™ ctDNA test results correlate to responses to ICIs and how Signatera™ can help physicians and patients in treatment planning.
Is Signatera™ right for your patients on immunotherapy?
1Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1:873–881. https://doi.org/10.1038/s43018-020-0096-5
2Haslam A, et al. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535-e192535. https://doi.org/10.1001/jamanetworkopen.2019.2535
3Haslam A, et al. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw Open. 2020;3(3):e200423. https://doi.org/10.1001/jamanetworkopen.2020.0423